Theratechnologies Inc. (THTX) Bundle
Ever wondered about the story behind Theratechnologies Inc. (THTX), a biopharmaceutical company making waves in the healthcare sector? Founded in 1993, Theratechnologies has grown into a company with over 100 employees across Canada, the United States, and Europe, achieving a record revenue of $85.9 million in fiscal year 2024. Keep reading to explore its journey, from its initial focus on HIV treatments to its current expansion into oncology, and discover how it aims to redefine standards of care.
Theratechnologies Inc. (THTX) History
Theratechnologies Inc.'s Founding Timeline
Year established
The company was established in 1993.
Original location
The company is based in Montreal, Canada.
Founding team members
The founding and leadership team included individuals with expertise in pharmaceutical development and commercialization, though specific names are not always highlighted in general company overviews.
Initial capital/funding
Details on the initial capital and funding sources during the company’s inception are not readily available in general overviews. Typically, early-stage biotech companies rely on venture capital, angel investors, and government grants.
Theratechnologies Inc.'s Evolution Milestones
| Year | Key Event | Significance |
|---|---|---|
| 2003 | Approval of tesamorelin (Egrifta) in the United States | Marked the company's first major regulatory approval and entry into the market with a treatment for HIV-associated lipodystrophy. |
| 2018 | Approval of Trogarzo (ibalizumab-uiyk) in the United States | Expanded the company's portfolio with a novel treatment for multi-drug resistant HIV-1 infection, addressing a critical unmet need. |
Theratechnologies Inc.'s Transformative Moments
- Strategic Shift to Focus on HIV and Oncology: A pivotal decision to concentrate research and development efforts on specific therapeutic areas, leveraging existing expertise and market opportunities.
- Acquisition and Licensing Agreements: Strategic moves to acquire or license promising drug candidates, enhancing the pipeline and diversifying revenue streams.
- Navigating Regulatory Challenges: Successfully navigating the complex regulatory landscape to secure approvals for key products, demonstrating the company's capabilities in drug development and compliance.
To gain more insights into the company's guiding principles, check out: Mission Statement, Vision, & Core Values of Theratechnologies Inc. (THTX).
Theratechnologies Inc. (THTX) Ownership Structure
Understanding the ownership structure of a company provides valuable insights into its control and governance. Here's a breakdown of Theratechnologies Inc.'s ownership, current status, and leadership.
Theratechnologies Inc.'s Current Status
Theratechnologies Inc. is a publicly traded company, meaning its shares are available for purchase by the general public on a stock exchange. It is listed on the Toronto Stock Exchange (TSX) under the ticker symbol THT and on the Nasdaq Capital Market under the ticker symbol THTX.
Theratechnologies Inc.'s Ownership Breakdown
The ownership of Theratechnologies Inc. is distributed among various shareholders, including institutional investors, individual investors, and company insiders. The following table summarizes the ownership breakdown:
| Shareholder Type | Ownership, % | Notes |
|---|---|---|
| Institutional Investors | 54.28% | Includes investment firms, mutual funds, and other institutions. |
| Individual Investors | 44.94% | Shares held by retail investors. |
| Insiders | 0.78% | Shares held by company executives and board members. |
Theratechnologies Inc.'s Leadership
The leadership team plays a crucial role in guiding the strategic direction and operational performance of Theratechnologies Inc. Key members of the leadership team include:
- Paul Lévesque: President and Chief Executive Officer
- Philippe Dubuc: Senior Vice President and Chief Financial Officer
- Dr. Christian Marsolais: Senior Vice President and Chief Medical Officer
These individuals, along with other members of the executive team and the Board of Directors, are responsible for making key decisions and overseeing the company's operations. For more insights into the company's financial standing, check out: Breaking Down Theratechnologies Inc. (THTX) Financial Health: Key Insights for Investors
Theratechnologies Inc. (THTX) Mission and Values
A biopharmaceutical company, focuses on unmet medical needs to promote the health and well-being of people with infectious diseases and cancer. You can explore more about the company's mission and vision on this page: Mission Statement, Vision, & Core Values of Theratechnologies Inc. (THTX).
[Company's] Core Purpose
Official mission statement
The official mission statement is to address unmet medical needs in order to promote the health and well-being of people with infectious diseases and cancer.
- Focuses on specialty products for unmet medical needs.
- Aims to serve people living with infectious diseases, including human immunodeficiency virus (HIV).
- Committed to patients with cancer.
Vision statement
The company strives to become a leading player in the treatment of metabolic disorders associated with HIV and to make a difference for patients, their families, and their healthcare providers.
- To be a leader in treating metabolic disorders linked to HIV.
- To positively impact patients, families, and healthcare providers.
Company slogan/tagline
The company doesn't have a formal slogan or tagline. Instead, it focuses on its mission and vision, emphasizing its commitment to addressing unmet medical needs in infectious diseases and cancer.
- No official slogan or tagline.
- Focus on mission to address unmet medical needs.
- Commitment to infectious diseases and cancer treatment.
Theratechnologies Inc. (THTX) How It Works
Theratechnologies Inc. operates as a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs, particularly in metabolic disorders and HIV. The company generates revenue through the sale of its proprietary pharmaceutical products.
Theratechnologies' Product/Service Portfolio
| Product/Service | Target Market | Key Features |
|---|---|---|
| EGRIFTA SV (tesamorelin for injection) | HIV patients with excess abdominal fat (lipodystrophy) | A synthetic peptide analog of growth hormone-releasing factor (GRF) that reduces excess abdominal fat in HIV-infected patients with lipodystrophy. |
| Trogarzo (ibalizumab-uiyk) | Multi-drug resistant HIV-1 infected adults | A long-acting, humanized monoclonal antibody for HIV-1 infected adults failing their current antiretroviral regimen. |
| Trozac (ibalizumab-uiyk) IV | Heavily treatment-experienced (HTE) adults living with multidrug-resistant HIV-1 (MDR HIV-1) infection. | Post-attachment inhibitor that binds to the domain 2 of the CD4 receptor on T-cells and interferes with the entry of HIV-1 into cells. |
| Fenesu | People living with HIV who have HIV-associated lipodystrophy | A novel formulation of tesamorelin, is designed to offer improved convenience and tolerability compared to EGRIFTA SV. |
Theratechnologies' Operational Framework
Theratechnologies operates through several key processes to create and deliver value:
- Research and Development: The company invests in R&D to discover and develop new therapies, focusing on areas with unmet medical needs.
- Manufacturing and Supply Chain: Theratechnologies relies on contract manufacturing organizations (CMOs) to produce its pharmaceutical products.
- Regulatory Affairs: Navigating the regulatory landscape is crucial. They work closely with health authorities like the FDA and EMA to secure approvals for their products.
- Commercialization: Theratechnologies markets and sells its products through its own sales force in some regions and through partnerships in others.
- Distribution: The company ensures its products are available to patients through established distribution channels.
Theratechnologies' Strategic Advantages
Theratechnologies has several strategic advantages that contribute to its success:
- Specialized Focus: The company's focus on niche markets, such as HIV-related complications, allows it to develop specialized expertise and targeted therapies.
- Proprietary Products: EGRIFTA SV and Trogarzo are proprietary products with patent protection, providing a competitive advantage.
- Strategic Partnerships: Collaborations with other pharmaceutical companies and research institutions expand Theratechnologies' reach and capabilities.
- Experienced Management Team: A strong management team with experience in the pharmaceutical industry guides the company's strategy and operations.
To gain more insights into the investors of Theratechnologies Inc., you can explore this resource: Exploring Theratechnologies Inc. (THTX) Investor Profile: Who’s Buying and Why?
Theratechnologies Inc. (THTX) How It Makes Money
Theratechnologies Inc. primarily generates revenue through the development and commercialization of specialized pharmaceutical products, focusing on addressing unmet medical needs in areas such as HIV and oncology.
Theratechnologies Inc.'s Revenue Breakdown
| Revenue Stream | % of Total | Growth Trend |
|---|---|---|
| Trogarzo (ibalizumab-uiyk) | Approximately 65% | Stable to Increasing |
| EGRIFTA and EGRIFTA SV (tesamorelin) | Approximately 35% | Stable |
Theratechnologies Inc.'s Business Economics
The company's business economics are influenced by several key factors:
- Pricing Strategy: The company employs premium pricing for its specialized medications, reflecting the high value and limited competition in their respective markets.
- Market Access: Securing and maintaining market access through reimbursement agreements with payers is critical.
- Production Costs: Efficient manufacturing and supply chain management are essential to maintaining profitability.
- Research and Development: Continued investment in R&D to expand the product pipeline and improve existing products.
Theratechnologies Inc.'s Financial Performance
Theratechnologies' financial performance can be assessed through the following points:
- In 2024, Theratechnologies reported total revenues of $79.2 million, a 15% increase compared to $68.7 million in 2023.
- For 2024, Trogarzo product sales increased by 18.8% to $51.9 million, compared to $43.7 million in 2023.
- EGRIFTA and EGRIFTA SV net sales increased to $27.3 million in 2024, up from $25.0 million in 2023.
- Gross profit for 2024 was $39.4 million, representing 49.8% of total revenues.
- Operating expenses for 2024 totaled $49.8 million.
- Net loss for 2024 was $13.5 million, an improvement from the $23.9 million loss reported in 2023.
To gain a deeper understanding of the company's financial standing, read more here: Breaking Down Theratechnologies Inc. (THTX) Financial Health: Key Insights for Investors
Theratechnologies Inc. (THTX) Market Position & Future Outlook
Theratechnologies Inc. is strategically positioned in the specialty pharmaceutical sector, focusing on innovative therapies for unmet medical needs. The company's future outlook is shaped by its ability to expand its product portfolio and navigate the competitive landscape.
Competitive Landscape
| Company | Market Share, % | Key Advantage |
|---|---|---|
| Theratechnologies Inc. | Estimated at 3-5% in key product areas | Specialized focus on niche markets with limited competition. |
| Gilead Sciences | 25-30% | Extensive resources and a broad portfolio of HIV/AIDS treatments. |
| Merck & Co. | 20-25% | Established global presence and diverse pharmaceutical offerings. |
Opportunities & Challenges
| Opportunities | Risks |
|---|---|
| Expanding the market for Trogarzo by securing approvals in new geographies and patient populations. | Competition from generics and biosimilars could erode market share and pricing power. |
| Developing and commercializing new therapies, such as the investigational agent for NASH, to diversify the product portfolio. | Clinical trial failures or regulatory setbacks could delay or halt the development of new products. |
| Leveraging strategic partnerships and collaborations to expand market reach and access new technologies. | Dependence on third-party manufacturers and suppliers could disrupt supply chains and increase costs. |
Industry Position
Theratechnologies occupies a unique space within the pharmaceutical industry, characterized by:
- Niche Focus: Concentrating on specific therapeutic areas with unmet needs, allowing for specialized expertise and targeted market penetration.
- Innovation: Investing in research and development to bring novel therapies to market, addressing critical gaps in treatment options.
- Strategic Partnerships: Collaborating with other companies and organizations to expand market reach and leverage complementary capabilities.
For more insights into the company's guiding principles, explore: Mission Statement, Vision, & Core Values of Theratechnologies Inc. (THTX).
Theratechnologies Inc. (THTX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.